Case Report Malignant Transformation of Heterotopic Pancreatic Tissue in a Patient with BRCA2

Danson Xue Wei Yeo 1, Nicholette Goh 1,*, Khoon Leong Chuah 2, Sanghvi Kaushal Amitbhai 1, Aung Myint Oo 1, Abdul Kareem Saleem Ahmed 1 and Koura Aaryan Nath 1

1 Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore; [email protected] (D.X.W.Y.); [email protected] (S.K.A.); [email protected] (A.M.O.); [email protected] (A.K.S.A.); [email protected] (K.A.N.) 2 Department of , Tan Tock Seng Hospital, Singapore 308433, Singapore; [email protected] * Correspondence: [email protected]

Abstract: Background: Malignant transformation of heterotopic pancreatic tissue is a rare entity with only several case reports published in the scientific literature. Adjuvant chemotherapy following oncological resection for lesions with nodal metastasis has not been well described and there are no guidelines available to guide the management of these patients. Case Presentation: We present a case of gastric heterotopic pancreatic carcinoma with nodal metastasis in a young patient with breast gene (BRCA) 2 mutation. He had undergone a laparoscopic wedge resection for a gastric lesion initially thought to be a gastrointestinal stroma tumor. Given the involvement of the wedge resection margins, the patient underwent a distal gastrectomy with oncological lymph nodal clearance. One out   of the 33 harvested lymph nodes harboured micrometastasis while the main gastrectomy specimen did not have any residual . Following the histological diagnosis, he received an adjuvant Citation: Yeo, D.X.W.; Goh, N.; chemotherapy regime akin to that prescribed for locally advanced pancreatic Chuah, K.L.; Amitbhai, S.K.; Oo, with good response. This is, to our knowledge, also the first such case report in a patient with A.M.; Ahmed, A.K.S.; Nath, K.A. BRCA2 mutation. Conclusions: Pre-operative diagnostic confirmation is challenging and endoscopic Malignant Transformation of Heterotopic Pancreatic Tissue in a procedures pose significant false negatives. Reports of nodal metastasis following oncological Patient with BRCA2 Mutation. resection are limited and there are no guidelines regarding adjuvant therapies. We would recommend Gastroenterol. Insights 2021, 12, 10–16. a chemotherapy regimen similar to that for primary locally advanced pancreatic carcinoma in patients https://doi.org/10.3390/ found to have nodal metastasis. gastroent12010002 Keywords: heterotopic pancreas; adenocarcinoma; BRCA gene mutation Received: 26 October 2020 Accepted: 27 December 2020 Published: 19 January 2021 1. Introduction Publisher’s Note: MDPI stays neutral Heterotopic pancreatic tissue can be found in various locations of the gastrointestinal with regard to jurisdictional claims in tract and malignant transformation of this tissue is exceedingly rare with only a few published maps and institutional affil- documented cases in scientific literature. Following oncological resection of these lesions, iations. adjuvant therapy for those with a positive nodal status has not been well described and guidelines with regards to management of these patients are lacking. The authors present a young male patient with gastric heterotopic pancreatic carcinoma with nodal metastasis who was subsequently detected to have the gene (BRCA) 2 mutation. He had Copyright: © 2021 by the authors. good response to adjuvant chemotherapy following oncological resection. This is to our Licensee MDPI, Basel, Switzerland. knowledge, the first such case report in a patient with BRCA2 mutation. This article is an open access article distributed under the terms and 2. Case Report conditions of the Creative Commons Attribution (CC BY) license (https:// We present a case of a 33-year-old Chinese male initially presenting with dyspepsia for creativecommons.org/licenses/by/ which an oesophagoduodenoscopy was performed. This revealed a submucosal bulge with 4.0/). central umbilication at the antrum (Figure1), and a subsequent computed tomographic (CT)

Gastroenterol. Insights 2021, 12, 10–16. https://doi.org/10.3390/gastroent12010002 https://www.mdpi.com/journal/gastroent Gastroenterol. Insights 2021, 12 11

scan of the abdomen and pelvis showed a 2.3-cm enhancing nodule over the anterior aspect of the pylorus suggestive of a gastrointestinal tract stromal tumour (GIST) (Figures2 and3) . The patient underwent laparoscopic wedge resection of the tumour. Histopathological assessment (Figure4) demonstrated the presence of heterotopic pancreatic tissue displaying cellular proliferation resembling acinar cells and ducts of the pancreas. An adjacent invasive adenocarcinoma comprising malignant glands was present and demonstrated areas of central necrosis and perineural invasion. The tumour extended to the radial and deep margins. On immunohistochemistry, the tumour showed positive staining for CK7 and focal staining for CDX2 was noted. The stains for synaptophysin, chromogranin, TTF-1, CK20 and Gata3 were negative. ki-67 proliferative index was in the region of 75%. The findings were consistent with a pancreatic ductal adenocarcinoma arising from heterotopic pancreas within the stomach.

Figure 1. Endoscopic photograph of submucosal bulge with central umbilication.

Figure 2. Computed tomographic scan image (transverse cuts) demonstrating the gastric pylorus tumour. Gastroenterol. Insights 2021, 12 12

Figure 3. Computed tomographic scan image (coronal cuts) demonstrating the gastric pylorus tumour.

Figure 4. (A). Low-power view revealing the presence of heterotopic pancreatic tissue with acinar cells (star) and pancreatic ducts (asterisk) in the submucosa of the stomach. (H&E ×40); (B). Medium- power view showing malignant glands invading the muscularis layer of the stomach with accompa- nying desmoplasia (H&E, ×100). Gastroenterol. Insights 2021, 12 13

A CT scan of the thorax after the first surgery confirmed no distant metastasis. Given the involvement of the wedge resection margins, the patient underwent a distal gastrectomy with oncological lymph nodal clearance. One out of the 33 harvested lymph nodes harboured micrometastasis while the main gastrectomy specimen did not have any residual malignancy. Postoperatively, the patient underwent adjuvant chemotherapy with oxaliplatin, irinotecan, folinic acid and fluorouracil (FOLFOXIRI). The chemotherapy regime was guided by the standard of care for pancreatic cancer after discussion at our multidisciplinary tumour board meeting. A CT scan of the thorax, abdomen and pelvis one year after the surgery did not demonstrate any evidence of local recurrence or metastasis. Tumour markers were not assessed prior to surgery, however cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) levels have remained within the normal range after the surgery. Following surgery, a discussion regarding hereditary cancer syndromes was held with the patient and he was offered genetic testing consisting of the following genes: APC, ATM, BMPR1A, BRCA1, BRCA2, CDKN2A (p14ARF), CDKN2A (p16INK4a), EPCAM, MEN1, MLH1, MSH2, MSH3, MSH6, NF1, PALB2, PMS2, SMAD4, STK11, TP53, TSC1, TSC2, VHL. This returned as positive for a pathogenic variant in the BRCA2 gene, whereby c.7007 + 1G > C (splice donor) was reported. Of note, he does not have a significant family history of malignancy and genetic screening was also offered to his first-degree family members. The patient will continue to be closely followed up for other BRCA2-related like breast and prostatic cancer.

3. Discussion This rare entity of heterotopic pancreatic tissue was first described in 1727 where it was identified by Schultz as an ileal diverticulum and thereafter proven histologically by Klob in 1859 [1]. It has since been found in various locations of the gastrointestinal tract where the most common locations include the stomach, followed by the duodenum, jejunum (accounting for more than 70% of cases) [2,3] and more uncommonly the esophagus, ileum, Meckel diverticulum and biliary tree [4,5]. In the stomach, it has a predilection for the antrum and prepyloric region [6]. Albeit likely under-reported due to its presentation as an incidental finding in most cases, the reported incidence in autopsy studies and upper abdominal surgeries ranges from 0.5% to 13.7% [7]. A further rarity would be the presence of malignant transformation within the heterotopic pancreatic tissue. The incidence of malignant transformation of heterotopic pancreatic tissue is less than 2% [8]. The diagnostic criteria proposed by Guillou et al. to confirm that the malignancy indeed arises from heterotopic pancreatic tissue can be summarized into three main points. Firstly, the tumour must be found within, or close to the aberrant pancreatic tissue. Sec- ondly, identification of a transitional area between pancreatic structures and carcinoma. Lastly, there has to be evidence of pancreatic acini and/or ductal structures seen within the non-neoplastic heterotopic pancreatic tissue [9]. Although the diagnosis of ectopic pancreatic tissue is often incidental, the majority of patients with malignancy are symptomatic at presentation with abdominal pain being the predominant complaint in more than half [10]. These ectopic pancreatic tumours are most commonly found in the stomach and a subepithelial tumour-like appearance is most frequently observed. With histological analysis, adenocarcinoma is the commonest subtype. It is interesting to note that in patients with ectopic pancreatic adenocarcinoma, the rate of having an elevated serum tumour marker is lower than that compared to primary pancreatic cancer [10,11]. It remains a challenge to obtain pre-operative confirmation of the diagnosis with con- ventional imaging like endoscopic ultrasound or computed tomographic scans as they often reveal a nonspecific mass. Common differentials include gastrointestinal tract stromal tumours (GIST), carcinoid tumours and gastric . More than half of ectopic pancreatic tissue is located within the submucosal layer, while less than a fifth are located within the submucosa and muscularis propria [12]. Given that the commonest location for these tumours is the gastric antrum, endoscopic ultrasound should be a consideration. Ectopic pancreatic tissue is Gastroenterol. Insights 2021, 12 14

identified based not only on its location within the gastrointestinal wall, but also described to be a poorly defined, low echoic mass with an area of internal spotty high echo inside with a spindle-shaped, thickened muscularis propria neighbouring the lesion [12,13]. However, in majority of the cases described in literature, surgical resection was performed following the initial diagnosis of other tumours like GIST or gastric cancers and the final histology of ectopic pancreatic cancer was confirmed based on the resected surgical specimen [10]. Endo et al. described the diagnosis of malignancy based on pre- operative biopsy and have advocated for the use of endoscopic biopsy such as endoscopic ultrasonography-guided, fine-needle aspiration (EUS-FNA) and endoscopic mucosal resec- tion with a transparent plastic cap-fitted panendoscope (EMR-C) followed by a biopsy [10]. Nonetheless, there appears to be a significant false negative rate in the biopsy of submucosal lesions—up to 60% in a series by Matsuki et al. [14]. Besides breast and ovarian cancer, germline in BRCA2 significantly in- creases the risk of pancreatic cancer with a relative risk of 3.51 [15]. While familial pancre- atic cancers account for 5–10% of pancreatic cancers [16], Goggins et al. [17] found that the incidence of germline BRCA2 mutations in apparently sporadic pancreatic cancer may be at least as high (7.3%) as in breast or ovarian cancer, even in patients without family history, suggestive of an inherited predisposition to cancer. There are reports of earlier onset of pancreatic cancer is cases with BRCA2 mutations, with a mean age of 53–62 years [18,19], however 5 year survivals are no different from that of pancreatic cancer patients without genetic mutations. Pancreatic cancer may result from the germline mutations in various cancer susceptibility genes such as BRCA1, BRCA2, TP53, PALB2, p16/CDKN2A, SMAD4, STK11, ataxia-telangiectasia-mutated (AM) gene and mismatch repair (MMR) genes [16]. To date, there are no clear guidelines for the management of malignant ectopic pan- creas. Authors have recommended local excision for lesions proven to be benign and extensive resection with oncological lymph nodal clearance for malignant lesions [20]. As such, pre-operative confirmation of the neoplastic process would be beneficial. There are limited reports of adjuvant therapy following oncological resection of these tumours. Hickman et al. describe that the course of ectopic pancreatic carcinomas within the stomach appear to behave like primary gastric cancers and suggest that they be managed in a similar fashion [21], while other patients underwent adjuvant chemotherapy similar to that for pancreatic cancer [22]. There is no available literature on the efficacy of chemotherapy for adenocarcinoma arising from a heterotopic pancreas [23]. In our patient, the adjuvant chemotherapy regime was akin to that prescribed for locally advanced pancreatic adenocar- cinoma, for which in the recent PRODIGE 4/ACCORD 11 randomized trials, a four-drug regimen called FOLFIRINOX demonstrated to prolong overall survival compared to con- ventional gemcitabine monotherapy [24]. Given his BRCA2 status, the patient will continue to be closely followed-up for other associated malignancies like prostatic cancer and his family members have also been offered genetic screening. In terms of follow-up for the malignant ectopic pancreas, the surveillance with regular cross-sectional imaging would not differ from that of locally advanced pancreatic adenocarcinoma.

4. Conclusions Adenocarcinoma arising from heterotopic pancreatic tissue as a result of a BRCA2 mutation is exceedingly rare. Pre-operative diagnostic confirmation is challenging and en- doscopic procedures pose significant false negatives. Reports of nodal metastasis following oncological resection are limited and there are no guidelines regarding adjuvant thera- pies. We would recommend a chemotherapy regimen similar to that for primary locally advanced pancreatic carcinoma in patients found to have nodal metastasis. When atypical cancers are found in young patients, genetic counselling should be strongly considered after discussion with the patient. Gastroenterol. Insights 2021, 12 15

Author Contributions: Conceptualization, data curation, literature review, writing of original draft, review and editing, D.X.W.Y. and N.G. Pathohistological analysis, review and editing, K.L.C. Review and editing S.K.A., A.M.O. and A.K.S.A. Main attending consultant of patient, supervision, K.A.N. All authors have read and agreed to the published version of the manuscript. Funding: This research received no external funding. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Consent to publish the personal and clinical details (including figures) has been obtained from the patient. Data Availability Statement: Not applicable. Conflicts of Interest: The authors declare no conflict of interest.

References 1. Hunt, V.C. Meckel’s diverticulum containing abberant pancreas. Arch. Surg. 1934, 28, 425–439. [CrossRef] 2. Goodarzi, M.; Rashid, A.; Maru, D. Invasive ductal adenocarcinoma arising from pancreatic heterotopia in rectum: Case report and review of literature. Hum. Pathol. 2010, 41, 1809–1813. [CrossRef][PubMed] 3. Stock, C.; Keutgen, X.M.; Pisapia, D.; Crawford, C.; Zarnegar, R. Heterotopic pancreatic neoplasm presenting as an obstructing mass at the fourth portion of the duodenum. JOP 2011, 12, 241–243. [PubMed] 4. Ulrych, J.; Fryba, V.; Skalova, H.; Krska, Z.; Krechler, T.; Zogala, D. Premalignant and malignant lesions of the heterotopic pancreas in the esophagus: A case report and review of the literature. J. Gastrointest. Liver Dis. 2015, 24, 235–239. [CrossRef] [PubMed] 5. Kung, J.W.; Brown, A.; Kruskal, J.B.; Goldsmith, J.D.; Pedrosa, I. Heterotopic pancreas: Typical and atypical imaging findings. Clin. Radiol. 2010, 65, 403–407. [CrossRef] 6. Song, D.E.; Kwon, Y.; Kim, K.R.; Oh, S.T.; Kim, J.S. Adenocarcinoma arising in gastric heterotopic pancreas: A case report. J. Korean Med. Sci. 2004, 19, 145–148. [CrossRef][PubMed] 7. Herold, G.; Kraft, K. Adenocarcinoma arising from ectopic gastric pancreas: Two case reports with a review of the literature. Z. Gastroenterol. 1995, 33, 260–264. 8. Yamaoka, Y.; Yamaguchi, T.; Kinugasa, Y.; Shiomi, A.; Kagawa, H.; Yamakawa, Y.; Numata, M.; Sugimoto, S.; Imai, K.; Hotta, K.; et al. Adenocarcinoma arising from jejunal ectopic pancreas mimicking peritoneal metastasis from colon cancer: A case report and literature review. Surg. Case Rep. 2015, 1, 114. [CrossRef] 9. Guillou, L.; Nordback, P.; Gerber, C.; Schneider, R.P. Ductal adenocarcinoma arising in a heterotopic pancreas situated in a hiatal hernia. Arch. Pathol. Lab. Med. 1994, 118, 568–571. 10. Endo, S.; Saito, R.; Ochi, D.; Yamada, T.; Hirose, M.; Hiroshima, Y.; Yamamoto, Y.; Ueno, T.; Hasegawa, N.; Moriwaki, T.; et al. Effectiveness of an endoscopic biopsy procedure using EUS-FNA and EMR-C for diagnosing adenocarcinoma arising from ectopic pancreas: Two case reports and a literature review. Intern. Med. 2014, 53, 1055–1062. [CrossRef] 11. Safi, F.; Schlosser, W.; Falkenreck, S.; Beger, H.G. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998, 45, 253–259. [PubMed] 12. Yasuda, K.; Nakajima, M.; Yoshida, S.; Kiyota, K.; Kawai, K. The diagnosis of submucosal tumors of the stomach by endoscopic ultrasonography. Gastrointest. Endosc. 1989, 35, 10–15. [CrossRef] 13. Matsushita, M.; Hajiro, K.; Okazaki, K.; Takakuwa, H. Gastric aberrant pancreas: EUS analysis in comparison with the histology. Gastrointest. Endosc. 1999, 49, 493–497. [CrossRef] 14. Matsuki, M.; Gouda, Y.; Ando, T.; Matsuoka, H.; Morita, T.; Uchida, N.; Kuriyama, S. Adenocarcinoma arising from aberrant pancreas in the stomach. J. Gastroenterol. 2005, 40, 652–656. [CrossRef][PubMed] 15. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 1999, 91, 1310–1316. [CrossRef][PubMed] 16. Iqbal, J.; Ragone, A.; Lubinski, J.; Lynch, H.T.; Moller, P.; Ghadirian, P.; Foulkes, W.D.; Armel, S.; Eisen, A.; Neuhausen, S.L.; et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 2012, 107, 2005–2009. [CrossRef] 17. Goggins, M.; Schutte, M.; Lu, J.; Moskaluk, C.A.; Weinstein, C.L.; Petersen, G.M.; Yeo, C.J.; Jackson, C.E.; Lynch, H.T.; Hruban, R.H.; et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996, 56, 5360–5364. [PubMed] 18. Phelan, C.M.; Lancaster, J.M.; Tonin, P.; Gumbs, C.; Cochran, C.; Carter, R.; Ghadirian, P.; Perret, C.; Moslehi, R.; Dion, F.; et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat. Genet. 1996, 13, 120–122. [CrossRef] 19. Couch, F.J.; Johnson, M.R.; Rabe, K.G.; Brune, K.; de Andrade, M.; Goggins, M.; Rothenmund, H.; Gallinger, S.; Klein, A.; Petersen, G.M.; et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 2007, 16, 342–346. [CrossRef] 20. Jeng, K.S.; Yang, K.C.; Kuo, S.H. Malignant degeneration of heterotopic pancreas. Gastrointest. Endosc. 1991, 37, 196–198. [CrossRef] Gastroenterol. Insights 2021, 12 16

21. Hickman, D.M.; Frey, C.F.; Carson, J.W. Adenocarcinoma arising in gastric heterotopic pancreas. West. J. Med. 1981, 135, 57–62. [PubMed] 22. Kaneko, T.; Ohara, M.; Okamura, K.; Fujiwara-Kuroda, A.; Miyasaka, D.; Yamabuki, T.; Takahashi, R.; Komuro, K.; Suzuoki, M.; Iwashiro, N.; et al. Adenocarcinoma arising from an ectopic pancreas in the duodenum: A case report. Surg. Case Rep. 2019, 5, 126. [CrossRef] [PubMed] 23. Fukino, N.; Oida, T.; Mimatsu, K.; Kuboi, Y.; Kida, K. Adenocarcinoma arising from heterotopic pancreas at the third portion of the duodenum. World J. Gastroenterol. 2015, 21, 4082–4088. [CrossRef][PubMed] 24. Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardiere, C.; et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364, 1817–1825. [CrossRef][PubMed]